Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Earlier we have shown the expression of a constitutively active receptor tyrosine kinase Axl in CLL B-cells from previously untreated CLL patients, and that Axl inhibitor TP-0903 induces robust leukemic B-cell death. To explore whether Axl is an effective target in relapsed/refractory CLL patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324680/
https://www.ncbi.nlm.nih.gov/pubmed/30647852
http://dx.doi.org/10.18632/oncotarget.26444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324680/
https://www.ncbi.nlm.nih.gov/pubmed/30647852
http://dx.doi.org/10.18632/oncotarget.26444

Ejemplares similares